Operose Advisors’s Omnicell OMCL Stock Holding History

Operose Advisors’s Portfolio OMCL Stock Details OMCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-328	Closed	-$14.8K	–	692
2023 Q3	$14.8K	Buy	+328	New	+$19.9K	0.01%	521

Other funds holding OMCL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Operose Advisors's OMCL Position: Q4 2023 in Review

Operose Advisors sold out of Omnicell (OMCL) in Q4 2023, closing a stake of 328 shares — an estimated $14.8K sold.

Operose Advisors first reported a position in OMCL in Q3 2023 and held it in 1 quarter. The position peaked at $14.8K in Q3 2023. 290 funds tracked by Wall St. Rank hold OMCL as of Q4 2023.

Operose Advisors reported no remaining Omnicell position as of Q4 2023 after selling out during the quarter.
Operose Advisors sold 328 Omnicell shares in Q4 2023, an estimated $14.8K.
Operose Advisors first reported a position in Omnicell in Q3 2023 and held it in 1 quarter.
Operose Advisors's Omnicell position peaked at $14.8K in Q3 2023.
290 funds tracked by Wall St. Rank held Omnicell as of Q4 2023.

Based on Operose Advisors's 13F filing for Q4 2023, filed 12 Feb 2024.